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Sulfated	  glycosaminoglycans	  (GAGs)	  are	  polysaccharides	  which	  are	  the	  most	  complex	  glycans	  
in	  nature,	  with	  roles	  in	  a	  wide	  range	  of	  crucial	  biological	  functions	  that	  are	  also	  relevant	  to	  
many	  disease	  processes.	  Their	  complex	  patterns	  of	  sulfation	  permit	  them	  to	  bind	  and	  regulate	  
cognate	   proteins,	   and	   repesents	   a	   kind	   of	   molecular	   code	   that	   underpins	   their	   selective	  
modes	  of	  action.	  However,	  determining	  the	  structure-­‐function	  relationships	  of	  this	  code	  has	  
remains	   a	   significant	   challenge	   to	   progress	   in	   the	   field,	   due	   to	   the	   inherent	   difficulties	   in	  
analysis	  of	  these	  glycans	  and	  the	  lack	  of	  analytical	  tools.	  	  Now	  two	  labs	  have	  harnessed	  gene	  
editing	   techniques	   to	   engineer	   stable	   changes	   in	   the	   cellular	   machinery	   that	   produces	  
GAGs1,2,	   in	   particular	   exploiting	   	   recently	   developed	   clustered	   regularly	   interspaced	   short	  
palindromic	  repeat	  (CRISPR)-­‐CRISPR-­‐associated	  gene	  9	  (Cas9)	  as	  a	  rapid	  and	  relatively	  simple	  
route	  to	  stable	  knockout	  cell	   lines.	   	   In	  doing	  so	  they	  have	  created	  new	  cell	  variants	  which	  
produce	   divergent	   and	   novel	   GAG	   structures	   that	   represent	   a	   rich	   resource	   to	   propel	  
advances	  in	  the	  field.	  	  
Chen	   et	   al1	   developed	   a	   cell	   library	   resource	   described	   as	   the	   “GAGome”	   using	   widely	  
exploited	  Chinese	  hamster	  ovary	  (CHO)	  cells	  as	  their	  model	  system.	  Using	  CRISPR-­‐Cas9	  they	  
developed	   a	   validated	   set	   of	   guide	   RNAs	   (gRNAs)	   and	   employed	   these	   to	   knock-­‐out	   (KO)	  
specific	  combinations	  of	  genes,	  along	  with	  some	  selected	  gene	  knock-­‐ins	  using	  established	  
zinc	  finger	  nuclease	  (ZFN)-­‐based	  approaches.	  This	  permitted	  large-­‐scale	  combinatorial	  gene	  
engineering	   of	   a	  wide	   variety	   of	   genes	   in	   the	  biosynthetic	   pathway	   for	  GAGs	  of	   both	   the	  
chondroitin/dermatan	  sulfate	  (CS/DS)	  and	  heparan	  sulfate	  (HS)	  families.	  In	  contrast,	  Qiu	  et	  
al2	   focussed	   on	   the	   HS	   family	   genes	   in	   primary	   lung	   endothelial	   cells,	   exploiting	   Cre-­‐Lox	  
recombination	  technology	  and	  a	  number	  of	  existing	  mutant	  mice	  strains	  (as	  well	  as	  additional	  
application	  of	  CRISPR-­‐Cas9	  in	  some	  cases)	  to	  derive	  a	  diverse	  library	  with	  combinatorial	  KO	  of	  
expression	  of	  key	  biosynthetic	  and	  remodelling	  enzymes.	  
In	  previous	  work	  mutant	  CHO	  cell	  lines	  derived	  by	  classical	  chemical	  mutation	  methods	  have	  
been	   a	   powerful	   tool3,	   along	   with	   more	   recent	   availability	   of	   KO	   cell	   lines	   derived	   from	  
transgenic	  mice	  (with	  mainly	  single	  or	  dual	  combinations	  of	  altered	  enzymes)4.	  	  Combinatorial	  
application	  of	  the	  small	  interfering	  RNA	  (siRNA)	  approach	  in	  cell	  lines	  has	  also	  been	  usefully	  
employed5.	  These	  certainly	  have	  experimental	  value	  but	  also	  limitations	  in	  scope.	  In	  contrast,	  
the	  advantages	  of	   the	  new	  platforms	  are	   the	  ability	   to	  produce	  systematically	  engineered	  
isogenic	   variants	   on	   larger	   scale,	   and	   in	   a	   wider	   variety	   of	   cell	   types,	   thus	   dramatically	  
expanding	  the	  potential	  scale	  of	  such	  methodologies	  (see	  Figure).	  
The	  new	  cell	  libraries	  were	  validated	  by	  showing	  how	  combinatorial	  mutants	  could	  effectively	  
tackle	  key	  questions	  in	  the	  field.	  Firstly	  the	  cells	  provide	  the	  basis	  for	  a	  powerful	  new	  genetic	  
dissection	   strategy	   to	  explore	   the	  biosynthetic	  and	   remodeling	  processes	   involved	   in	  GAG	  
production;	   in	   concert	   with	   structural	   analysis	   of	   GAG	   disaccharide	   composition	   they	  
provided	   further	   insights	   into	   the	   complex	   inter-­‐regulation	   of	   the	   network	   of	   enzymes	  
involved1,2,	   including	   effects	   on	   chain	   length2.	   Secondly,	   the	   cells	   were	   used	   in	   binding	  
experiments	   to	   show	   that	   they	   could	   be	   used	   to	   explore	   the	   specificity	   of	   GAG-­‐protein	  
interactions,	   exemplified	   by	   growth	   factors,	   pathogen	   receptors	   and	   antibodies1,2.	  	  	  
Furthermore,	  the	  functional	  impact	  of	  the	  engineered	  changes	  could	  be	  examined	  in	  terms	  
of	  endogenous	  signaling	  responses	  to,	  for	  example,	  growth	  factors2.	  Importantly,	  these	  data	  	  
provided	   further	   evidence	   that	   structure-­‐activity	   relates	   to	  HS	   fine	   structure	   and	   not	   just	  
sulfation	  levels,	  and	  that	  nuanced	  relationships	  exist	  between	  binding	  and	  functional	  effects2.	  
Finally,	   it	   was	   demonstrated	   that	   the	   engineered	   cells	   could	   be	   used	   to	   produced	   novel	  
products	  with	  defined	  GAG	  chains,	  including	  recombinant	  proteoglycans,	  	  or	  secreted	  GAG	  
chains	  “primed”	  with	  xylosides	  (as	  a	  proxy	  for	  the	  natural	  core	  protein)1.	  The	  latter	  could	  also	  
provide	  a	  chemical	  tag	  at	  one	  end	  of	  the	  chain	  which	  could	  be	  exploited	  in	  the	  future	  to	  permit	  
their	  oriented	  attachment	  to	  surfaces	  including	  glycoarrays1.	  	  
	  
These	   new	   technologies	   now	   provide	   almost	   boundless	   opportunities	   for	   expanding	   the	  
libraries	  and	  exploiting	  them	  in	  a	  broad	  range	  of	  applications	   (see	  Figure).	  Crucially,	   these	  
tools	  will	  appeal	  not	  only	  to	  existing	  glycobiology	  aficionados	  but	  will	  surely	  open	  up	  the	  field	  
to	  wider	   life	  and	  biomedical	   sciences	   researchers	  previously	   reluctant	   to	  grapple	  with	   the	  
complexities	   of	   GAG	   functions,	   despite	   their	   evident	   importance.	   In	   particular	   the	   use	   of	  
CRISPR-­‐Cas9	  with	  validated	  sets	  of	  gRNA	  targeting	  constructs1	  will	  enable	  studies	  in	  virtually	  
any	  cell	  type	  in	  the	  future.	  The	  opportunities	  for	  cell–based	  screening	  extend	  beyond	  using	  
the	  cells	   in	  binding	  studies,	  since	  they	  will	  allow	  extensive	  dissection	  of	  structure-­‐function	  
relationships	  in	  specific	  cell	  contexts.	  They	  can	  also	  be	  exploited	  to	  better	  define	  bioactive	  
GAG	   motifs	   of	   biological	   relevance	   (especially	   domain	   structures	   reflected	   by	   longer	  
sequences	  of	  disaccharides),	  to	  address	  key	  questions	  about	  selectivity	  of	  GAG	  structures	  for	  
protein	  interactions,	  and	  also	  regulation	  of	  the	  biosynthetic	  network.	  A	  key	  opportunity	  will	  
be	  to	  better	  understand	  the	  role	  of	  3-­‐O-­‐sulfation	  of	  HS,	  a	  rare	  event	  which	  involves	  a	  family	  
of	  at	  least	  seven	  enzymes	  but	  whose	  functional	  role	  is	  currently	  poorly	  understood.	  
	  
The	   cell	   lines	  also	  provide	  a	   rich	  new	   resource	   for	   creating	  novel	  GAG-­‐based	   compounds,	  
including	  content	   for	  populating	  microarrays	  with	  defined	  GAG	  chains	   to	  measure	  binding	  
capacities6	  and	  potentially	  live	  cell	  signaling	  responses7.	  The	  derived	  GAGs	  could	  also	  be	  used	  
to	  generate	  defined	  bioactive	  saccharide	  libraries8	  for	  screening	  in	  biochemical	  and	  bioassays	  
relevant	   to	   many	   different	   biological	   processes.	   Collectively	   the	   exploitation	   of	   these	  
resources	  should	  yield	  a	   step-­‐change	   in	   insights	   into	   the	  structure-­‐activity	   relationships	  of	  
GAGs,	  and	  could	  underpin	  identification	  of	  new	  drug	  candidates.	  Finally,	  the	  cell	  libraries	  will	  
also	  provide	  a	  potentially	  scaleable	  “recombinant”	  source	  of	  novel	  defined	  GAG	  chain	  and	  PG	  
biomaterials	  for	  applications	  including	  regenerative	  medicine9.	  	  
	  
Together	  with	  ongoing	  advances	  in	  mass	  spectrometry	  techniques	  for	  detailed	  sequencing	  of	  
bioactive	  GAG	  domains10	  these	  cell-­‐based	  libraries	  and	  derived	  resources	  hold	  huge	  promise	  
to	   alleviate	   the	   current	   bottleneck	   in	   our	   understanding	   of	   selectivity	   in	   GAG-­‐protein	  
interactions.	  	  This	  can	  ultimately	  be	  expected	  to	  underpin	  major	  new	  advances	  in	  biomedical	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Figure	   legend:	   Systematic	   cell-­‐based	   GAG	   libraries	   and	   related	   resources:	   exploring	  
specificity	  and	  generating	  novel	  bioactive	  entities.	  
Recent	  	  gene	  editing	  techniques	  can	  be	  leveraged	  to	  engineer	  libraries	  of	  cell	  lines	  with	  stable	  
changes	   in	   the	   cellular	   machinery	   that	   produces	   complex	   polysaccharides	   of	   the	  
glycosaminoglycan	   (GAG)	   family.	   This	   provides	   a	   rich	   new	   resource	   for	   exploring	   their	  
structure-­‐activity	  relationships	  in	  diverse	  biological	  processes	  underpinning	  many	  diseases.	  	  
Exploiting	  these	  libraries	  to	  the	  full	  holds	  the	  potential	  to	  create	  a	  step-­‐change	  in	  the	  field	  
and	   drive	   advances	   in	   downstream	   applications	   such	   as	   discovery	   of	   novel	   drugs	   and	  
biomaterials.	  
	  
	  	  
